

Anti-IL23 α (Risankizumab), Humanized Antibody

08/20

CATALOG NO.: A2204-100 (100 μ g)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of IL-23 α . IL-23 is a pro-inflammatory cytokine that is primarily secreted by dendritic cells, monocytes, and macrophages. It is a heterodimeric complex that consists of p19 and p40 subunit. p19 subunit is unique for IL-23 whereas the p40 subunit is shared with IL-12. IL-23 plays an important role in the pathogenesis of inflammatory diseases such as psoriasis. Binding of the antibody to IL-23 α prevents the interaction with IL-23 receptor and thereby inhibits inflammatory responses. The original drug received approval from the FDA to treat patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

ALTERNATE NAMES: 655066-01, ABBV-066, BI 655066, P19, SGRF, IL-23, IL23A, IL23P19

ANTIBODY TYPE: Monoclonal

CONCENTRATION: 1 mg/ml

HOST/ISOTYPE: Recombinant / IgG1, kappa

SOURCE: CHO cells

IMMUNOGEN: Human IL23 α

CAS NUMBER: 1612838-76-2

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

STORAGE CONDITIONS: Store at -80°C

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-IL-23 α (Guselkumab), Human IgG1 Antibody (A2147)
 Anti-IL-23 α (Tildrakizumab), Humanized Antibody (A2159)
 Anti-IL-12 β (Ustekinumab), Human IgG1 Antibody (A2137)
 Anti-IL-17 α (Ixekizumab), Humanized Antibody (A2149)
 Anti-TNF- α (Adalimumab), humanized Antibody (A1048)

FOR RESEARCH USE ONLY! Not to be used on humans.